No profile data available.
Larimar Therapeutics, Inc. (LRMR) is a healthcare company in the brain and nerve treatment drugs industry, based in Bala Cynwyd, United States, with about 71 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$165.67 million. Its market capitalization was $277.37 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Larimar Therapeutics reported $0 in revenue for fiscal year 2025.
$277.37 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Relmada Therapeutics, Inc. (RLMD), Benitec Biopharma Inc. (BNTC), Fulcrum Therapeutics, Inc. (FULC), Vanda Pharmaceuticals Inc. (VNDA).